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Background.TheAllergyLateralFlowAssay(ALFA)isanovelrapidassayforthedetection ofsIgEtoallergens. Theobjective ofthis
study is the evaluation of ALFA for the detection of sIgE to bee venom (BV) and wasp venom (WV) in insect venom allergic pa-
tients. Methods. Speciﬁc IgE to BV and WV was analyzed by ALFA, ALLERG-O-LIQ, and ImmunoCAP in 80 insect venom allergic
patients and 60 control sera. Sensitivity and speciﬁcity of ALFA and correlation of ALFA and ImmunoCAP results were calculated.
Results. The sensitivity/speciﬁcity of ALFA to the diagnosis was 100%/83% for BV and 82%/97% for WV. For insect venom allergic
patients,theSpearmancorrelationcoeﬃcientforALFAversusImmunoCAPwas0.79forBVand0.80forWV.However,signiﬁcant
diﬀerences in the negative control groups were observed. Conclusion. ALFA represents a simple, robust, and reliable tool for the
rapid detection of sIgE to insect venoms.
1.Introduction
Reliable diagnosis of insect venom allergy is based on the
combinationofpatient’shistory,skintesting(SPT)andlabo-
ratory tests for the detection of speciﬁc IgE (sIgE) [1–4].
The methodology for the measurement of sIgE has evol-
ved during the recent years [5, 6]. Lately, rapid assays for
the detection of sIgE as point-of-care diagnostics have been
developed using various strategies [7, 8]. ALFA, the Allergy
Lateral Flow Assay (Dr. Fooke Laboratorien GmbH, Neuss,
Germany), combines the advantages of lateral ﬂow devices
with the ﬂexibility of choosing diﬀerent allergens as already
shown for cat epithelia (e1), Dermatophagoides pteronyssinus
(d1),Alternariaalternata(m6),birchpollen(t3)[9],andalso
in depth for timothy grass pollen (g6) [10]. In contrary
to other rapid tests like the ImmunoCAP Rapid (Phadia,
Uppsala, Sweden) [8], which employs a ﬁxed panel of single
allergens immobilized on membranes, ALFA utilizes liquid
allergens and allergen mixtures. The open architecture of the
ALFA system allows for the selection of the required aller-
gen in combination with a universal basis set (see Figure 1).
Biotinylated insect venoms of honey bee, Apis mellifera (BV)
andwasp,Vespulavulgarisandgermanica(WV)werecharac-
terized and prepared for use with ALFA. The objective of this
study was the evaluation of ALFA, for the detection of sIgE
to bee venom (BV) and wasp venom (WV) in a well-deﬁned
cohort of patients. Sera were also analyzed by ImmunoCAP
(Phadia, Uppsala, Sweden) and ALLERG-O-LIQ (Dr. Fooke
Laboratorien GmbH). The correlation between methods was
calculated, and agreement between ALFA and the diagnosis
(basedonpatient’shistory,positiveskintest,anddetectionof
sIgE by ImmunoCAP (≥0.35kU/L)) was determined.
2. Patients andMethods
Sera of four groups were analyzed as follows.
(A) 40 patients with insect venom allergy to either bee
(n = 12) or wasp (n = 28) venom with agreement
of patient’s history, sIgE against the given venom
by ImmunoCAP and skin test. Mean age 41.8y
(SD 14.96y). 23 (57.5%) males, 17 (42.5%) females.2 Journal of Allergy
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Figure 1: Principle of ALFA. A test cassette showing a positive test
result is presented in (a) and the principle of the test in (b). The
patient’s sample is transferred to the sample application point.
Immediately afterwards the allergen solution of interest is applied.
During incubation time of 20min, the liquid is driven through the
device by capillary ﬂow. Allergen speciﬁc IgE of the sample binds
speciﬁcally to the corresponding antigens of the allergen solution.
The antigens are labeled and are retained at the test line (T) by a
capture molecule. Atthesame timethe sIgEboundto theallergen is
bound by an antibody coupled to colored particles (conjugate). The
intensity of the color reaction at the test line is proportional to the
amount of immune complexes consisting of ligand tagged antigens,
sIgE, and IgE speciﬁc conjugate. The signal intensity ranges from
faintly pink (low titer of sIgE) to dark ruby (high titer of sIgE).
Access conjugate, which is not bound at the test line, will form a
dark ruby control line (C) after 20min of incubation.
3 (7.5%) Patients presented with anaphylactic reac-
tions grade 1 (according to Ring and Messmer [11,
12]), 23 (57.5%) with anaphylactic reaction grade 2
and 14 (35%) with anaphylactic reaction grade 3 to
insect venom sting. None of the patients presented
with a grade 4 anaphylaxis. None of the patients
were under immunosuppressive medication or spe-
ciﬁc immunotherapy. Mean total IgE was 78.7kU/L
(range 11.6–372kU/L).
(B) 40patientswithinsectvenomallergyanddoublesen-
sitization (serological)tobee andwaspvenom, deter-
mined by ImmunoCAP, patient’s history and skin
test. Mean age 42.25y (SD 17.5y). 20 (50%) males,
20 (50%) females. 4 (10%) Patients presented with
anaphylactic reactions grade 1 (according to Ringb
and Messmer [11, 12]), 27 (67.5%) with anaphylactic
reaction grade 2 and 9 (22.5%) with anaphylactic
reaction grade 3 to insect venom sting. None of the
patients presented with a grade 4 anaphylaxis. None
of the patients were under immunosuppressive med-
ication or speciﬁc immunotherapy. Mean total IgE
was 150.5kU/L (range 16.5–667kU/L).
(C) Atopic individuals (Sx1 positive, total IgE mean =
2986kU/L, range 186–23813kU/L, history of at least
one atopic disease) without history of insect venom
allergy (n = 30). Mean age 33.5y (SD 15.75y).
16(53.34%)males,14(46.67%)females.19(63.34%)
patients presented with atopic dermatitis, 12 (40%)
patients with allergic rhinoconjunctivitis, and 7
(23.34%) with allergic asthma (some patients pre-
sentedwithtwoorthreemanifestations).Noneofthe
patients were under immunosuppressive medication
or speciﬁc immunotherapy.
(D) Non atopic individuals without history of insect
venom allergy (n = 30). None of the patients were
under immunosuppressive medication or speciﬁc
immunotherapy. Mean total IgE was 35.60kU/L
(range 2–99.3kU/L).
Diagnosis of insect venom allergy was based on patient’s
history (anaphylaxis due to bee or wasp sting [11, 12]),
positive skin test, and detection of sIgE by ImmunoCAP
(≥0.35kU/L).
2.1. Skin Test. In patients with insect venom allergy, skin
prick tests with increasing concentrations of BV and WV (1,
10,100μg/mL)(ALK-Abello,Reinbeck,Germany)wereper-
formed. If negative, intradermal tests at 1μg/mL were added
as recommended by the position paper of the EAACI Interest
GrouponInsectVenomHypersensitivity[13,14].Histamine
chlorideataconcentrationof1mg/mLservedaspositiveand
saline solution (0.9%) as negative control.
2.2. Detection of sIgE. All sera in this study (n = 140) were
assayed for sIgE to BV and WV by ALFA, ALLERG-O-LIQ,
areversed-type,quantitative,WHO75/502calibratedimmu-
noassay [1], and ImmunoCAP according to the instructions
given by the manufacturer. Speciﬁc IgE values >100IU/mL
were considered as 100IU/mL. ALFA results were quantiﬁed
by a scanning device with an appropriate software [10],
which measures the colour intensity of the test line and eval-
uates the validity of the test run by measuring the existence
and intensity of the control line. All samples were measured
after the same incubation time of 20min. The test values are
converted into relative units (RUs). Using individually dilu-
ted allergen solutions, the test kits are validated for identical
discriminationofpositiveandnegativeresults.Cut-oﬀvalues
were set using ROC-decision analysis made with Analyze-it
v2.21 for Excel (data not shown).
2.3. Statistical Analysis. Spearman correlation, P-values (1-
tailed Student’s t-test), and Receiver Operating Characteris-
tic analysis were performed with GraphPad Prism Ver. 5.01.
3. Results and Discussion
3.1. Detection of sIgE to Bee and Wasp Venom. When com-
pared to the diagnosis (based on patients history, skin test,
and sIgE detection by ImmunoCAP) comparative receiver
operating characteristic analysis of groups A and B revealed
area under the curve values for ALFA of 0.97 (BV) and 0.91
(WV).
In monosensitized patients (group A only), 12/12BV
allergic patients and 23/28WV allergic patients were pos-
itive in ALFA using a cut-oﬀ value for ALFA of 10.0RU,Journal of Allergy 3
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Figure 2:ReceiveroperatingcharacteristicofALFAandALLERGO-LIQforthediagnosisofbee(a)andwasp(b)venomallergyinmonosen-
sitized patients (group A) and control groups (C and D). Curve with dots indicates results for ALFA and curve with squares for ALLERGO-
LIQ. Diagnosis of insect venom allergy was based on patient’s history, skin testing, and detection of sIgE to bee or wasp venom by
ImmunoCAP. Sensitivity/speciﬁcity for ALFA is 100%/83% (BV) and 82%/97% (WV) at a cut-oﬀ value of 10.0RU and 100%/93% (BV) and
82%/93% (WV) for ALLERG-O-LIQ.
corresponding to a sensitivity of 100% for BV and 82% for
WV. Similar results were obtained by ALLERG-O-LIQ. In
ALLERG-O-LIQ 12/12BV allergic patients and 24/28WV
allergic patients were found positive (Figure 2).
For groups A and B high agreement between ALFA,
ALLERG-O-LIQ, and skin tests of up to 92% was observed
(data not shown). Using atopic (without history of insect
venom allergy—group C) and nonatopic (group D) sera as
controls, the speciﬁcity of ALFA for the detection of sIgE
to BV was calculated as 83% and for sIgE to WV as 97%
(Figure 2).
3.2. Comparison of ALFA and ImmunoCAP. For insect
venom allergic patients (groups A and B) the Spearman cor-
relation coeﬃcient for ALFA versus ImmunoCAP was 0.79
(P<0.0001) for BV and 0.80 (P<0.0001) for WV (data not
shown).CorrelationofALFAtoImmunoCAPforeachgroup
revealed a more deﬁned picture. For the detection of sIgE
to BV the Spearman correlation coeﬃcient for ALFA versus
ImmunoCAP was 0.72 (P<0.0001) for group A, 0.86 (P<
0.0001) for group B, 0.07 (ns) for group C, and 0.18 (ns)
for group D (Figure 3). For the detection of sIgE to WV the
Spearman correlation coeﬃcient for ALFA versus Immuno-
CAP was 0.82 (P<0.0001) for group A, 0.84 (P<0.0001)
for group B, 0.25 (ns) for group C, and 0.31 (P<0.05)
for group D (Figure 4).
These results demonstrate a good quantitative agreement
for the detection of sIgE to BV and WV between ALFA and
ImmunoCAP for sera of allergic patients (groups A and B)
butpoorquantitativeagreementforthecontrolgroups,espe-
cially for BV (groups C and D). This seems to be caused by a
surprisingly high number of positive ImmunoCAP results in
the control groups, in particular in the group of atopic indi-
viduals (without history of insect venom allergy) with high
total IgE-a ﬁnding that has been described before for diﬀe-
rent allergens [15, 16]. In the present study in group C (ato-
pic individuals with high total IgE) 19/30 (63.3%) of the
samples were BV positive by ImmunoCAP compared to 4/30
(13.3%) samples tested positive by ALFA. For WV 9/30
(30.0%) samples tested positive by ImmunoCAP and 1/30
sample (3.3%) by ALFA. In group D positive BV results were
observed for 3/30 sera (10%) by ImmunoCAP and 6/30
(20.0%) samples tested positive using ALFA. For WV the
results in group D showed 4/30 (13.3%) positive tests by
ImmunoCAP and 1/30 (3.3%) positive samples for ALFA,
respectively, (Table 1). The diﬀerent results of ALFA and
ImmunoCAP in relation to total IgE level of the patient are
shown in Figure 5.
Since sIgE to CCDs (cross-reactive carbohydrate deter-
minants) can be responsible for major cross-reactivity of gly-
cosylated allergens (e.g., of pollen, foods, insect venom, etc.),
sIgE to CCDs could also account for the high rate of BV
ImmunoCAP positives in the atopic negative controls
(Group C). However analyzing CCD reactivity by Immuno-
CAP showed that only less than 50% of the ImmunoCAP BV
positive sera also displayed CCD reactivity (data not shown).4 Journal of Allergy
Table 1: Results for the detection of bee and wasp venom of ALFA and ImmunoCAP for group A (n = 40), group B (n = 40), group C
(n = 30), and group D (n = 30).
ImmunoCAP ALFA (cut-oﬀ 10 RU)
Bee venom
positive
Bee venom
negative
Wasp venom
positive
Wasp venom
negative
Bee venom
positive
Bee venom
negative
Wasp venom
positive
Wasp venom
negative
Group A 12 28 28 12 17 23 23 17
Group B 36 4 39 1 27 13 30 10
Group C 19 11 9 21 4 26 1 29
G r o u p D 32 742 662 412 9
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Figure 3: Spearman correlation diagram of ALFA versus ImmunoCAP for the detection of sIgE to bee venom. Quantitative agreement was
found with a Spearman correlation coeﬃcient of 0.72 (P<0.0001) for group A (a), 0.86 (P<0.0001) for group B (b), 0.07 (P = 0.37) for
group C (c), and of 0.18 (P = 0.17) for group D (d) for the detection of sIgE to BV.Journal of Allergy 5
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Figure 4: Spearman correlation diagram of ALFA versus ImmunoCAP for the detection of sIgE to wasp venom. Quantitative agreement was
found with a Spearman correlation coeﬃcient of 0.82 (P<0.0001) for group A (a), 0.84 (P<0.0001) for group B (b), 0.25 (P = 0.088) for
group C (c), and of 0.31 (P = 0.047) for group D (d) for the detection of sIgE to WV.
This suggests that the high rate of BV positive results by
ImmunoCAP in atopic patients (without history of insect
venom allergy) with strongly elevated total IgE levels (mean
= 2986kU/L, range 186–23813kU/L) cannot be explained by
CCD reactivity but rather may reﬂect nonspeciﬁc IgE bind-
ing due to the solid phase architecture of the ImmunoCAP
assay system.
Recently recombinant allergens have been introduced
into the in vitro diagnostic of insect venom allergy. In par-
ticular for dissecting true double sensitization from cross-
reactivity recombinant allergens seems to be of great rele-
vance [17–19]. Since ALFA’s open architecture allows for the
use of any biotinylated allergen, the introduction of recom-
binant bee and wasp venom allergens will be useful and will
certainly further increase the clinical sensitivity and speci-
ﬁcity.
4. Conclusion
Detection of sIgE to bee and wasp venom by ALFA shows in
the present study a good discrimination between sera of bee
or wasp allergic patients and control sera with a compara-
ble performance to the ALLERG-O-LIQ and ImmunoCAP
system. Noteworthy ALFA detected no sIgE to BV in WV6 Journal of Allergy
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Figure 5: Graphical illustration of the relation of total IgE (green diamond, determined by ImmunoCAP) and sIgE to BV (red) and WV
(blue) for ImmunoCAP (a) and ALFA (b) for each study group.
allergic patients and vice versa. In case of speciﬁcity, a high
degree of correlation was found for ALFA and ALLERG-
O-LIQ, whereas diﬀering results were obtained using the
ImmunoCAP system.
We conclude that the Allergy Lateral Flow assay together
with the novel scanner-based system represents a versatile
andreliabletoolforthemeasurementofsIgEtoinsectvenom
allergens meeting the growing demand for digital documen-
tation of laboratory results. Further studies with more aller-
gens (e.g., recombinant insect venom allergens) are man-
datory to further proof the applicability of the ALFA test
system.
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